TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
TELA Bio (NASDAQ: TELA) will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026.
Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a corporate update. Investors must register at least one day ahead or 15 minutes before the call. A live webcast and replay will be available on TELA's investor Events & Presentations page.
Details
News Market Reaction – TELA
On Mar 11, the first trading day after this news, TELA closed 7.35% below the previous close.
Data tracked by StockTitan Argus for the Mar 11 session.
Key Figures
- Earnings report date
- March 24, 2026
- Scheduled Q4 and full year 2025 financial results release
- Earnings call time
- 4:30 p.m. ET
- Conference call and webcast to discuss 2025 results
Historical Context
-
RSU inducement grants for new hires under Nasdaq Rule 5635(c)(4).
-
Restricted stock unit grants to five newly hired employees.
-
RSU inducement grants totaling 3,600 shares to new employees.
-
Participation in Piper Sandler 37th Annual Healthcare Conference.
-
Equity awards including 30,200 RSUs and a 25,000-share option grant.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
soft-tissue reconstruction medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Fourth Quarter Earnings Conference Call and Webcast Details
Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the Events & Presentations page of the investor section of TELA's website.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.